EUVIMEDEUVIMED entdecken
Crossref

Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality

Elisabet Viayna, Eric A Gehrie iD, Christopher Blanchette

Transfusion · 2024

DOI: 10.1111/trf.17966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Elisabet Viayna und 2 weiteren Autor:innen. Beteiligte Einrichtung: Grifols S.A. Sant Cugat del Vallès, Barcelona, Spain. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Grifols, SSNA, Grifols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transfusion of red blood cells (RBC) is an important component of treatment for myelodysplastic syndromes (MDS). Patients receiving frequent transfusions are more likely to develop alloimmunization, an immune reaction to minor RBC antigens that increases the risk of complications including delayed hemolysis. Phenotypic matching is believed to reduce alloimmunization although rigorous evidence is lacking. This study examines the association of alloimmunization with clinical and economic outcomes and may give insight into the potential benefit of phenotypic matching in MDS. Study Design and Methods This study used data from 1054 hospitals included in the Premier hospital chargemaster dataset. Alloimmunized MDS patients (January 2015 to June 2019) were indirectly identified by ICD‐10 codes (antiglobulin crossmatch and RBC antibody identification). The primary objective was assessment of the association between incremental cost per patient encounter and alloimmunization in MDS patients. Secondary objectives were assessment of the association of length of stay, intensive care unit (ICU) admission, and inpatient mortality for alloimmunized versus non‐alloimmunized MDS patients.

Results

Worse clinical and economic outcomes were observed for the alloimmunized group. Higher costs (14%), more ICU admissions (38%), longer hospital (21%) and ICU stays (55%), and greater mortality (30%) were observed among alloimmunized MDS patients compared to non‐alloimmunized ( p < .0001 for all comparisons).

Discussion

Alloimmunization may be associated with higher costs and greater risk of ICU admission and death in patients with MDS. While further mechanistic research is needed, it seems that MDS patients may benefit substantially from practices that limit risk of alloimmunization, including providing prophylactic antigen matching.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesHumansMaleFemaleAgedMiddle AgedHealth Care CostsHospitalizationLength of StayErythrocyte TransfusionAged, 80 and overHospital Mortality

Stichwörter der Autor:innen

immunohematology (RBC serology, blood groups)transfusion complications—noninfectioustransfusion practices (adult)

Autor:innen und Institutionen

  • Grifols S.A. Sant Cugat del Vallès, Barcelona, Spain.
  • American Red Cross, Washington, DC, USA.
  • Rutgers University, New Brunswick, New Jersey, USA.

ORCID-Profile: Eric A Gehrie

Förderung

  • Grifols, SSNA
  • Grifols

Zitieren

APA

Viayna, E., Gehrie, E. A., & Blanchette, C. (2024). Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality. Transfusion. https://doi.org/10.1111/trf.17966

Vancouver

Viayna E, Gehrie EA, Blanchette C. Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality. Transfusion. 2024. doi:10.1111/trf.17966

BibTeX
@article{Viayna2024,
  author = {Viayna, Elisabet and Gehrie, Eric A and Blanchette, Christopher},
  title = {Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17966}
}
Kostenlos starten →